Docusign Envelope ID.. 14770F95-1E644728-A9EA-B67631C542AD
Registered number: 08236220
Charity numbers: 1154143 & SC045615
DEMENTIA RESEARCH UK
(A Company Limited by Guarantee)
CONSOLIDATED TRUSTEES. REPORT AND AUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 OCTOBER 2024

Docusign Envelope ID.. 14770F95-1E644728-A9EA-B67631C542AD
DEMENTIA RESEARCH UK
(A Company Limited by Guarantee)
CONTENTS
Page
Reference and administrative detsils of the Company. its Trustees and advisers
Trustees. report
Independent auditor's report on the financial statements
9-12
Consolidated statement of financial activities
13
Consolidated balance sheet
14
Company balance sheet
Consolidated statement of cash flows
15
16
Notes to the financial statements
17-28

Docusign Envelope ID.. 14770F95-1E644728-A9EA-B67631C542AD
DEMENTIA RESEARCH UK
(A Company Limited by Guarantee)
REFERENCE AND ADMINISTRATIVE DETAILS OF THE COMPANY. ITS TRUSTEES AND ADVISERS
FOR THE YEAR ENDED 31 OCTOBER 2024
Trustees
W Layl)oum
T Thompson (Resigned 31 October 2024)
L Bechelet (Resigned 31 December 2023)
J Runicles
A Gee (appointed 10 July 2024)
J Rogers (appointed 10 July 2024)
Company registered
number
08236220
Charity registered
numbers
1154143 and SC045615
Registered office
207 Regent Streel
London
W1B3HH
Company secretary
W La￿)ourn
Independent auditor
Cooper Parry Group Limited
Statutory Auditor
Cubo Birmingham
4th Floor
Two Chamberlain Square
Birmingham
83 3AX
Bankers
Unity Trust Bank
4 Brindley Place
Binningham
B1 2JB
CAF Bank Limited
25 Kings Hill Avenue
Kings Hill
West Malling
Kent
ME19 4JQ
Solicitors
Bates Wells
10 Queen Street Place
London
EC4R 1 BE
Page 1

Docusign Envelope ID.. 14770F95-1E644728-A9EA-B67631C542AD
DEMENTIA RESEARCH UK
(A Company Limited by Guarantee)
TRUSTEES. REPORT
FOR THE YEAR ENDED 31 OCTOBER 2024
The Trustees {who are also directors for the purposes of the Companies Act 2006) present their report with the
financial statements of the Group for the year ended 31 October 2024. The Trustees have adopted the
provisions of Accounting and Reporting by Charities= Statement of Recommended Practice applicable to
charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and
Republic of Ireland (FRS 102) (effective 1 January 2019).
Structure, governance and management
a. Constitution
The Company is registered as a charitable company limited by guarantee and was set up by a Memorandum of
Association on 2 October 2012.
The Company is constituted under a Memorandum of Association dated 2 October 2012 and is registered with
the Charity Commission number 1154143 and Scottish Charity Regulator number SC045615.
b. Methods of appointment or election of Trustees
The management of the company is the responsibility of the trustees who are elected and co-opted under the
terms of the Memorandum and Articles of Association.
The subscribers to the Memorandum were the first members of the charity. Members are responsible for
appointing the directors who also act as trustees. Currently, the charity trustees are the only voting members.
New trustees are appointed by resolution at a properly convened meeting of the existing charity trustees.
Appointments are made with a view to ensuring that the board comprises individuals with a diverse range of
management skills and qualities.
The Trustees who served during the period were as follows..
W Laybourn
T Thompson (resigned 31 October 2024)
L Bechelet (resigned 31 December 2023)
J Runicles
A Gee (appointed 10 July 2024)
J Rogers (appointed 10 July 2024)
Objectives and activities
a. Policies and objectives
The Memorandum and Articles of Association defines the objectives of the Group:
To protect and promote the health of the public in particular by research into the nature, causes, diagnosis,
prevention. treatment and care of all forms of dementia. including the development of findings of research into
the practical applications for the prevention and treatment of dementia and care of those suffering from dementia
and in furtherance of that primary object. to provide information and raise public awareness and understanding of
such matters.
b. Activities undertaken to achieve objectives
The Group carries out these objectives by funding research related to the treatment and cure of dementia and
related diseases. The research funded is both pure and applied. Pure research has the ultimate aim of
eradicating the disease while applied research is aimed at improving the lives of those living with dementia and
their carers.
Page 2

Docusign Envelope ID.. 14770F95-1E644728-A9EA-B67631C542AD
DEMENTIA RESEARCH UK
(A Company Limited by Guarantee)
TRUSTEES. REPORT (CONTINUED)
FOR THE YEAR ENDED 31 OCTOBER 2024
Objectives and activities {continued)
c. Public benefit
The Trustees confirm that they have referred to the guidance contained in the Charity Commission's general
guidance on public benefit when reviewing the Group s aims and objectives and in planning future activities.
Achievements and performance
Review of activities
The Group's grant-giving programme
The Group raises funds for research projects across the dementia community in all regions of the UK. The
Group's funding covers every type of dementia. rather than any individual disease. Consequently, the income
raised by the Group can be allocated across a wide range of research projects in the dementia community where
the Group's intention is to make a positive impact on as many people as possible who are living with any form of
dementia, together with their families and carers.
In funding research, the Group recognises the need to undertake pure research with the aim of alleviating and
eventually eradicating the disease, but it also recognises the needs of those living with dementia and the
research needed to improve the quality of their lives. Applied research, undertaken to help those on their
dementia journey, is centred on care and compassion. This type of research examines pattems of care in order
to meet appropriate and ever-changing needs together with the use of relevant. Up-to-date assistive technology.
Recent statistics now place dementia among the leading causes of death in the UK and the provision of end-of-
life care is a high priority for all concerned. The extent, availability and cost effectiveness of such care is an
unavoidable field for dementia research in the UK.
The Group's grant-giving programme cU￿entlY supports large-scale dementia research projects within
universities and hospitals, looking into new ways of diagnosing and treating dementia and into the availability of
end-of-life care for people with dementia. The Group also provides funds to regional centres across the UK
which deliver services and support directly to people with dementia, while carrying out research with those who
use their services to further identify new fomis of support.
The Group is very specific in its identification of potential grant recipients. Currently, applications for grants are
not actively sought. The Group carries out detailed research to identify organisations operating in the relevant
fields of pure and applied research. which adhere most closely to the Group's objectives.
The primary beneficiaries for the Group are those organisations which receive grants from the Group. Secondary
beneficiaries are those who benefit from the research and services provided by the grant recipients, i.e., people
with dementia, their families and carers and the health professionals who support them.
Pure research
The Dementia Research Centre at The National Hospital for Neurology and Neurosurgery has been the principal
recipient of the Group's grants for pure research. The work of the Research Centre, situated within University
College London. focuses on identifw'ng the disease processes that cause dementia with a view to understanding
the factors that influence those processes in order to find ways to improve diagnosis and treatment. A grant of
£100,000 has been awarded for this year (2023- £100.000).
Page 3

Docusign Envelope ID.. 14770F95-1E644728-A9EA-B67631C542AD
DEMENTIA RESEARCH UK
(A Company Limited by Guarantee)
TRUSTEES. REPORT (CONTINUED)
FOR THE YEAR ENDED 31 OCTOBER 2024
Achievements and performance (continued)
Applied research
Applied research grants are made in recognition of the fact that significant improvements in quality of life can be
achieved when people with dementia are seen as having a number of partially remediable disabilities, rather than
an ill-defined mix of irreversible cerebral incompetencies that is so often assumed. A number of Dementia
Services Development Centres (DSDCS) have been established which promote this concept across the UK. The
DSDC was originally developed by the Dementia servI￿s Development Trust (now The Dementia Trust) and
the charity has continued to award grants to the Trust, making a grant this year of £15,000 (2023- £37,500).
The DSDC in England, Trent Dementia, has been awarded an annual grant of £60,000 in 2024 (2023 - £50,000)
and the DSDC in Wales at Bangor University has been awarded £12,500 (2023 - £22,500).
The DSDCS are active in the provision of servI￿s, advice. social and practical support and events. They also
undertake research, centred on the needs of people with dementia, the results of which are used to develop new
and innovative services. Through their research and ongoing conversations with people with dementia, their
families and carers, the DSDCS are well-positioned to uncover areas of unmet need. The Group's role in
supporting the DSDC network enables the Group to help improve the day to day lives of people with dementia
and to identify the ServI￿S and support they may need in the future.
Remind UK (previously known as the Research Institute for the Care of Older People, or RICE) is an
intemationally renowned dementia research and treatment centre, with headquarters located in Bath. Remind UK
is an independent charity focused on essential research and providing support for people with dementia and
other conditions of older age. along with their families and carers. The charity's research wing is called The
Research Institute for Brain Health. They are currently delivering several cutting-edge research trials and studies
looking at brain function, the immune system. potential treatment for and management of dementia. A grant of
£15,000 was awarded to Remind UK in 2024 (2023 - £25.000).
End-of-life care
Dementia is among the leading causes of death in the UK but the extent and availability of end-of-life care for
dementia patients is variable and inconsistent. The imprecise boundaries of health and social care can be
perplexing to patients, carers and their families when seeking help at critical times. The funding of end-of-life
care can also vary between regions and health care providers. adding to an already confused picture. The Cicely
Saunders Institute based at Kings College London is a ￿ntre for research into the provision of end-of-life care in
the UK. A grant of £100,000 has been awarded to the Institute (2023 - £100,000) to assess the cost and
availability of end-of-life care for dementia patients. together with the potential for improving access to such care
throughout the UK.
Other grant recipients
The Group grant-making programme is constantly under review in order to identify potential new grant recipients.
The objectives are to pinpoint new organisations which fit the Group s criteria of conducting pure or applied
research, but which also provide opportunities for the Group to extend its grant-making impact into new areas of
dementia research or into new regions of the UK. Four new organisations were identified in 2023 which matched
the charivs grant-making objectives and which accepted the charitys offer of funding, as described below.
The research carried out by the Ageing and Dementia Research Centre (ADRC) at Boumemouth University falls
into three broad categories= developing ageing and dementia-friendly environments, nutrition and wellbeing, and
activity and social inclusion. The research carried out at the ADRC significantly impacts on theory, education and
professional practice relating to dementia. and the research team has developed a number of resources to guide
families, carers, and healthcare professionals on how best to help people with dementia. A grant of £20,000 was
awarded to the Centre in 2024.
Page 4

Docusign Envelope ID.. 14770F95-1E644728-A9EA-B67631C542AD
DEMENTIA RESEARCH UK
(A Company Limited by Guarantee)
TRUSTEES. REPORT (CONTINUED)
FOR THE YEAR ENDED 31 OCTOBER 2024
Achievements and performance (continued)
Dementia Prevention UK is a registered charity which provides education to men, women and children from
underserved communities on dementia risk factors and practical tools to prevent or delay dementia through
lifestyle modification. Their innovative research and workshop programmes focus on how behaviours can impact
the brain, and on the measures which individuals can take to maintain brain health and protect the brain. A grant
of £10.000 was awarded to Dementia Prevention UK in 2024.
Music for my Mind is a registered charity vthich promotes the use of personalised music as an effective therapy
for people who are living with dementia. Their research investigates how music can improve the wellbeing of
people with dementia and help to relieve anxiety and depression. The charity has developed new technology
which enables personalised Pla￿lstS to be created quickly and easily, based on an individual's background and
musical preferences, for use within a care home or an individual's own home. A grant of £15,000 was awarded to
Music for my Mind in 2024.
Memory Matters is a Community Interest Company that has been managing projects and services for people
with dementia for over 12 years. A Memory Matters Hub provides advice and practical support for anyone
concerned about memory loss or dementia. Memory Matters offers Cognitive Stimulation Therapy (CST) to help
those living with dementia to improve their cognitive abilities and quality of life and has developed the first CST e-
group therapy app, which can be used directly by someone who has dementia. A grant of £10,000 was awarded
to Memory Matters in 2024.
Group website
The Group launched its new website in January 2023. The key objectives of the new website are to showcase
more detailed infomiation about the impact of the Group and the scope of its grant-giving programme, whilst also
providing users with access to expert resources about dementia in order to support the Group's stated objective
'to provide information and raise public awareness and understanding of dementia,. Detailed information is
provided about all of the Group s grant recipients and the work undertaken. The Group now also benefits from
enhanced user analytics which have been established for the new website, helping to direct future content and
functionality.
Throughout the course of 2024, enhancements were made to the new website, including the introduction of a
weblog with content from expert contributors, the creation of a new 'Donate' page designed to facilitate donations
through a variety of online and offline channels and the introduction of measures to improve the website's search
engine optimisation or SEO. The continuing development of the website will inform the public about dementia
and help deliver new income streams for the Group, including the launch of its online store.
Trading company
In November 2022, the charity established a trading company, Dementia Research Trading Limited, to manage
its future trading operations.
Page 5

Docusign Envelope ID.. 14770F95-1E644728-A9EA-B67631C542AD
DEMENTIA RESEARCH UK
(A Company Limited by Guarantee)
TRUSTEES. REPORT (CONTINUED)
FOR THE YEAR ENDED 31 OCTOBER 2024
Financial review and future plans
a. Financial results for the year
In the financial year ending 31 October 2024, incoming resources toialled £947,406 (2023 - £1,048,256) resulting
from voluntary donations, legacies, and gift aid. Expenditure for the year totalled £1,051,67512023- £889,300},
consisting of raising funds £289,870 (2023- £213,709) and charitable activities £761,805 (2023.. £675,591 }. The
overall {deficit)Isurplus for the year amounted to (£104,269) {2023.. £158,956). This has resulted in an overall
carried forward balance within unrestricted funds of £359.894 (2023: £464,163).
b. Reserves policy
The Trustees review reserves regularly in order to ensure that the Group is in a position to meet all its current
and anticipated future commitments. Reserves are defined as that part of a Group's unrestricted funds that is
freely available to spend on any of the Group's purposes. As a matter of policy. reserves are held in order to
cover six months of anticipated expenditure whenever possible.
As of 31st October 2024, reserves of £360,000 were held representing approximately three months of
anticipated expenditure in the year ahead. In comparison. at 31st October 2023 reserves of £464.000 were held
representing five months of actual expenditure totalling £1.052.000 in the year under review.
The Group does not award grants for a period greater than twelve months and it only awards grants which are
covered by available reserves. The minimum level of reserves that the Group requires to meet its commitments
and continue trading in any twelve month period is estimated at £250.000.
c. Going concern
After making appropriate enquiries, the Trustees have a reasonable expectation that the Company has adequate
resources to continue in operational existence for the foreseeable future. For this reason, they continue to adopt
the going concem basis in preparing the financial statements. Further details regarding the adoption of the going
concem basis can be found in the accounting policies below.
d. Plans for the future
The success which the Group has seen in 2024 in tems of its fundraising retums will form the basis of its activity
in 2025. The website will be further developed to maximise income and user engagement and the careful use of
new data to target priority prospects will continue. The Group will build on its relationships with its grant recipients
via new content collaborations for the website together with new joint promotional and other fundraising activities.
The Group continues to ensure that the growth projects it pursues are realistic, sustainable. and have maximum
impact at minimum cost, whilst ensuring that fundraising activity and the income that fundraising generates, is
not disrupted. The Trustees do not anticipate any significant change to the cost of external resources required to
support the current activities of the Group. All the projects are managed in-house, with external resources only
being brought in where it is critical to the success of the project. Any additional resource required to support the
Group's new fundraising strategy will be kept to a minimum and will be subject to careful tendering and review
processes.
All the necessary insurances and legal obligations to support the Group's current activilies are in place and the
Group has conducted a full risk analysis of its operation. Any additional requirements for new projects will be put
in place as the relevant projects are implemented.
Page 6

Docusign Envelope ID.. 14770F95-1E644728-A9EA-B67631C542AD
DEMENTIA RESEARCH UK
(A Company Limited by Guarantee)
TRUSTEES. REPORT (CONTINUED)
FOR THE YEAR ENDED 31 OCTOBER 2024
Small company provisions
In preparing this report, the Trustees have taken advantage of the small companies exemptions provided by
section 415A of the Companies Act 2006.
Structure, governance and management
Principal risks and unceriainties
The trustees of the charity have considered the principal risks and Un￿rtaIntieS facing the organisation,
including=
1. Funding and Financial Stabilty. Reliance on donations and fundraising activities presents a risk if income
levels fuctuate or decline, potentially affecting the charity's ability to deliver services.
2. Governance and Compliance: Non-compliance with legal or regulatory requirements (such as data protection
or financial reporting) could result in reputational damage and penalties.
3. Operational Risks.. Disruption to key ServI￿S due to loss of staff, volunteers or essential partners.
4. Reputational Risk.. Negative publicity. complaints or incidents could adversely affect the charity's standing and
donor confiden￿.
5. External Environment: Changes in government policy. the economic climate or unforeseen events {such as
pandemics or natural disasters) may impact the chariws operations and funding.
6. IT and Data Security: The risk of cyber-attacks or data breaches could compromise sensitive information and
disrupt services.
The trustees regularfy review these risks and have mitgation plans in place, including robust financial controls
and contingency procedures to address potential threats. A risk register has also been established and is
updated regularly.
Page 7

Docusign Envelope ID.. 14770F95-1E644728-A9EA-B67631C542AD
DEMENTIA RESEARCH UK
(A Company Limited by Guarantee)
TRUSTEES. REPORT (CONTINUED)
FOR THE YEAR ENDED 31 OCTOBER 2024
Statement of Trustees. responsibilities
The Trustees {who are also the directors of the Company for the purposes of company law) are responsible for
preparing the Trustees. report and the financial statements in accordance with applicable law and United
Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).
Company law requires the Trustees to prepare financial statements for each financial year. Under company law,
the Trustees must not approve the financial statements unless they are satisfied that they give a true and fair
view of the state of affairs of the Group and the Company and of their incoming resources and application of
resources, including their income and expenditure, for that period. In preparing these financial statements, the
Trustees are required to-
select suitable accounting policies and then apply them consistently.,
observe the methods and principles of the Charities SORP (FRS 102).
make judgements and accounting estimates that are reasonable and prudent.
state whether applicable UK Accounting Standards (FRS 102) have been followed, subjecl to any material
departures disclosed and explained in the financial statements-
prepare the financial statements on the going cOn￿M basis unless it is inappropriate to presume that the
Group will continue in business.
The Trustees are responsible for keeping adequate accounting records that are sufficient to show and explain
the Group and the Companys transactions and disclose with reasonable accuracy at any time the financial
position of the Group and the Company and enable them to ensure that the financial statements comply wilh the
Companies Act 2006. They are also responsible for safeguarding the assets of the Group and Ihe Company and
hence for taking reasonable steps for the prevention and deteclion of fraud and other irregularities.
In so far as the Trustees are aware-
there is no relevant audit infomation of which the Group's audilor is unaware, and
the Trustees have taken all the steps that ought to have been taken as Trustees in order to be aware of any
relevant audit information and to establish that the Group's auditor is aware of that information.
Auditor
The auditor, Cooper Parry Group Limited, has indicated its willingness to continue in office. The designated
Trustees will propose a motion reappointing the auditor at a meeting of the Trustees in accordance with section
485 of the Companies Act 2006.
Approved by order of the members of the board of Trustees and signed on their behalf by..
3wJned by..
69A28A632S3C4E4..
J Rogers
Trustee
Date-29 July 2025
Page 8

Docusign Envelope ID.. 14770F95-1E644728-A9EA-B67631C542AD
DEMENTIA RESEARCH UK
(A Company Limited by Guarantee)
INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF DEMENTIA RESEARCH UK
Opinion
We have audited the financial statements of Dementia Research UK (the 'parent charitable companrf) and its
subsidiaries (the 'group') for the year ended 31 October 2024 which comprise the Consolidated statement of
financial activities, the Consolidated balan￿ sheet, the Company balance sheet, the Consolidated statement of
cash flows and the related notes. including a summary of significant accounting policies. The financial reporting
framework that has been applied in their preparation is applicable law and United Kingdom Accounting
Standards. including Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK
and Republic of Ireland, (United Kingdom Generally AC￿pted Accounting Practice).
In our opinion the financial statements=
give a true and fair view of the state of the Group's and of the parent charitable companvs affairs as at 31
October 2024 and of the Group's incoming resources and application of resources, including its income
and expenditure for the year then ended.,
have been properly prepared in accordan￿ with United Kingdom Generally Accepted Accounting
Practice., and
have been prepared in accordan￿ with the requirements of the Charities Act 2011, the Charities and
Trustee Investment (Scotland) Act 2005 and regulations 6 and 8 of the Charities Accounts {Scotland)
Regulations 2006.
Basis for opinion
We conducted our audit in accordance with International Standards on Auditing (UK} (ISAS (UK)) and applicable
law. Our responsibilities under those standards are further described in the Auditorfs responsibilities for the audit
of the financial statements section of our report. We are independent of the Group in accordance with the ethical
requirements that are relevant to our audit of the financial statements in the United Kingdom, including the
Financial Reporting Council's Ethical Standard, and we have fulfilled our other ethical responsibilities in
accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and
appropriate to provide a basis for our opinion.
Conclusions relating to going concern
In auditing the financial statements, we have concluded that the Trustees, use of the going concern basis of
accounting in the preparation of the finanaal statements is appropriate.
Based on the work we have performed, V￿ have not identified any material uncertainties relating to events or
conditions that, individually or collectively. may cast significant doubt on the Group's or the parent charitable
companls ability to continue as a going concem for a period of at least twelve months from when the financial
statements are authorised for issue.
Our responsibilities and the responsibilities of the Trustees with respect to going con￿rn are described in the
relevant sections of this report.
Page g

Docusign Envelope ID.. 14770F95-1E644728-A9EA-B67631C542AD
DEMENTIA RESEARCH UK
(A Company Limited by Guarantee)
INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF DEMENTIA RESEARCH UK (CONTINUED)
other information
The other information comprises the infomiation included in the Annual report other than the financial statements
and our Auditorfs report thereon. The Trustees are responsible for the other information contained within the
Annual report. Our opinion on the financial statements does not cover the other information and, except to the
extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. Our
responsibility is to read the other information and, in doing so, consider whether the other information is
materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or
otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material
misstatements, we are required to determine whether this gives rise to a material misstatement in the financial
statements themselves. If, based on the work we have performed, we conclude that there is a material
misstatement of this other information, we are required to report that fact.
We have nothing to report in this regard.
Matters on which we are required to report by exception
We have nothing to report in respect of the following matters where the Charities (Accounts and Reports)
Regulations 2008 and Charities Accounts (Scotland) Regulations 2006 (as amended) requires us to report to you
in our opinion..
the infomiation given in the Trustees. report is inconsistent in any material respect with the financial
statements., or
the parent charitable company has not kept sufficient and proper accounting records. or
the parent charitable company financial statements are not in agreement with the accounting records and
returns- or
we have not received all the information and explanations we require for our audit.
Responsibilities of Trustees
As explained more fully in the Trustees, responsibilities statement. the Trustees (who are also the directors of the
charitable company for the purposes of company law) are responsible for the preparation of the financial
statements and for being satisfied that they give a true and fair view, and for such internal control as the
Trustees determine is necessary to enable the preparation of financial statements that are free from material
misstatement, whether due to fraud or error.
In preparing the financial statements, the Trustees are responsible for assessing the Group's and the parent
charitable companls ability to continue as a going concern, disclosing, as applicable, matters related to going
concern and using the going concem basis of accounting unless the Trustees either intend to liquidate the Group
or the parent charitable company or to cease operations, or have no realistic alternative but to do so.
Page 10

Docusign Envelope ID.. 14770F95-1E644728-A9EA-B67631C542AD
DEMENTIA RESEARCH UK
(A Company Limited by Guarantee)
INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF DEMENTIA RESEARCH UK (CONTINUED)
Auditorfs responsibilities for the audit of the financial statements
We have been appointed as auditor under section 151 of the Charities Act 2011 and section 44(1)(cl of the
Charities and Trustee Investment (Scotland) Act 2005 and report in accordance with the Act and relevant
regulations made or having effect thereunder.
Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free
from material misstatement. whether due to fraud or error, and to issue an Auditor's report that includes our
opinion. Reasonable assuran￿ is a high level of assuran￿, but is not a guarantee that an audit conducted in
accordance with ISAS {UK) will always detect a material misstatement when it exists. Misstatements can arise
from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be
expected to influence the economic decisions of users taken on the basis of these financial statements.
Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures
in line with our responsibilities, outlined above. to detect material misstatements in respect of irregularities,
including fraud. The extent to which our prO￿dureS are capable of detecting irregularities, including fraud is
detailed below=
Our assessment focused on key laws and regulations the Group has to comply with and areas of the financial
statements we assessed as being more SUS￿ptib1e to misstatement. These key laws and regulations included
but were not limited to compliance with the Companies Act 2006, Charities Act 2011, Charities and Trustee
Investment {Scotland) Act 2005, taxation legislation. data protection, anti-bribery and employment legislation. We
are not responsible for preventing i￿egUla￿ties. including fraud. Our approach to detecting irregularities,
including fraud, included, but was not limited to, the following=
obtaining an understanding of the legal and regulatory framework applicable to the Group and how the
Group is complying with that framework. including agreement of financial statement disclosures to underlying
documentation and other evidence.
obtaining an understanding of the Group's control environment and how the Group has applied relevant
control procedures, through discussions with Truslees and other management and by performing
walkthrough testing over key areas.
obtaining an understsnding of the Group's risk assessment process, including the risk of fraud,.
reviewing meeting minutes of those charged with govemance throughout the year., and
performing audit testing to address the risk of management override of controls, including testing journal
entries and other adjustments for appropriateness, evaluating the business rationale of significant
transactions outside the nonnal course of business and reviewing accounting estimates for bias.
Whilst considering how our audit work addressed the detection of irregularities, we also considered the likelihood
of detection of fraud based on our approach. Irregularities arising from fraud are inherently more difficult to
detect than those arising from error.
Because of the inherent limitations of an audit. there is a risk that we will not detect all irregularities, including
those leading to a material misstatement in the financial statements or non-compliance with regulation. This risk
increases the more that compliance with a law or regulation is removed from the events and Iransaclions
reflected in the financial statements, as we will be less likely to become aware of instances of non-compliance.
The risk is also greater regarding irregularities occurring due to fraud rather than error, as fraud involves
intentional concealment, forgery, collusion, omission or misrepresentation.
A further description of our responsibilities for the audit of the financial statements is located on the Financial
Reporting Council's website at: www.frc.or
.ukJauditorsres
onsibilities. This description forms part of our
Auditor's report.
Page11

Docusign Envelope ID.. 14770F95-1E644728-A9EA-B67631C542AD
DEMENTIA RESEARCH UK
(A Company Limited by Guarantee)
INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF DEMENTIA RESEARCH UK (CONTINUED)
Use of our report
This report is made solely to the charitable CoMpan￿S trustees, as a body, in accordance with Part 4 of the
Charities {Accounts and Reports) Regulations 2008 and regulation 10 of the Charities Accounts (Scotland)
Regulations 2006. Our audit work has been underiaken so that we might state to the charitable companvs
trustees those matters we are required to state to them in an Auditor's report and for no other purpose. To the
fullest extent permitted by law. we do not accept or assume responsibility to anyone other than the charitable
company and its members. as a body, for our audit work. for this report, or for the opinions we have formed.
Cooper Parry Group Limited
Statutory Auditor
Cubo Birmingham
4th Floor
Two Chamberlain Square
Bimingham
B3 3AX
Date- 29 July 2025
Cooper Parry Group Limited are eligible to act as auditors in tems of section 1212 of the Companies Act 2006.
Page 12

Docusign Envelope ID.. 14770F95-1E644728-A9EA-B67631C542AD
DEMENTIA RESEARCH UK
(A Company Limited by Guarantee)
CONSOLIDATED STATEMENT OF FINANCIAL ACTIVITIES {INCORPORATING INCOME AND
EXPENDITURE ACCOUNT)
FOR THE YEAR ENDED 31 OCTOBER 2024
Unrestricted
funds
2024
Total
funds
2024
Total
funds
2023
Note
Income from:
Donations and legacies
947,406
947,406
1.048,256
Total income
947,406
947,406
1.048,256
Expenditure on:
Raising funds
Charitable activities
289,870
761,805
289,870
761,805
247,508
641,792
Total expenditure
1,051,675
1.051,675
889,300
Net movement in funds
{104,2691
(104,269)
158,956
Reconciliation of funds:
Total funds brought fO￿ard
Net movement in funds
464,163
(104,2691
464,163
{104,269}
305,207
158,956
Total funds carried forward
359,894
359,894
464,163
The Consolidated statement of financial activities includes all gains and losses recognised in the year.
The notes on pages 17 to 28 fonm part of these financial statements.
Page 13

Docusign Envelope ID.. 14770F95-1E644728-A9EA-B67631C542AD
DEMENTIA RESEARCH UK
(A Company Limited by Guarantee)
REGISTERED NUMBER: 08236220
CONSOLIDATED BALANCE SHEET
AS AT 31 OCTOBER 2024
2024
2023
Note
Current assets
Stocks
Debtors
13
14
18,048
101,064
300.333
42,970
542,302
Cash at bank and in hand
19
419,445
585,272
Creditors.. amounts falling due within one
year
15
(59,551)
1121,109)
Net current assets
359,894
464,163
Total net assets
359,894
464,163
Charity funds
Unrestricted funds
16
359,894
464,163
Total funds
359,894
464,163
The Company was entitled to exemption from audit under section 477 of the Companies Act 2006.
The members have not required the entity to obtain an audit for the year in question in accordance with section
476 of the Companies Act 2006.
However. an audit is required in accordance with section 151 of the Charities Act 2011 and section 44(1)(cl of
the Charities and Trustee Investment (Scotland) Act 2005.
The Trustees acknowledge their responsibilities for complwng with the requirements of the Act with respect to
accounting records and preparation of financial statements.
The financial statements have been prepared in accordance with the provisions applicable to entities subject to
the small companies regime.
The financial statements were approved and authorised for issue by the Trustees and signed on their behalf by-
3wJned by..
69A28A632S3C4E4..
J Rogers
Trustee
Date=29 July 2025
The notes on pages 17 to 28 form part of these financial statements.
Page 14

Docusign Envelope ID.. 14770F95-1E644728-A9EA-B67631C542AD
DEMENTIA RESEARCH UK
(A Company Limited by Guarantee)
REGISTERED NUMBER: 08236220
COMPANY STATEMENT OF FINANCIAL POSITION
AS AT 31 OCTOBER 2024
2024
2023
Note
Fixed assets
Investments
12
100,002
100,002
100,002
100,002
Current assets
Debtors
14
175.829
300,333
42,835
519,930
Cash at bank and in hand
19
476.162
562,765
Creditors.. amounts falling due within one
year
15
(77.961)
(108,650)
Net current assets
398,201
454,115
Total net assets
498,203
554,117
Charity funds
Unrestricted funds
16
498,203
554,117
Total funds
498,203
554,117
The Companvs net movement in funds for the year was £{55.914) (2023 - £248,910).
The Company was entitled to exemption from audit under section 477 of the Companies Act 2006.
The members have not required the entity to obtain an audit for the year in question in accordance with section
476 of the Companies Act 2006.
However. an audit is required in accordance with section 151 of the Charities Act 2011 and section 44(1)(cl of
the Charities and Trustee Investment (Scotland) Act 2005.
The Trustees acknowledge their responsibilities for complying with the requirements of the Act with respect to
accounting records and preparation of financial statements.
The financial statements have been prepared in accordance with the provisions applicable to entities subject to
the small companies regime.
The financial statements were approved and authorised for issue by the Trustees and signed on their behalf by:
3wJned by..
69A28A63253C4E4..
J Rogers
Trustee
Date- 29 July 2025
The notes on pages 17 to 28 form part of these financial statements.
Page 15

Docusign Envelope ID.. 14770F95-1E644728-A9EA-B67631C542AD
DEMENTIA RESEARCH UK
(A Company Limited by Guarantee)
CONSOLIDATED STATEMENT OF CASH FLOWS
FOR THE YEAR ENDED 31 OCTOBER 2024
2024
2023
Cash flows from operating activities
Net cash used in operating activities
(241,969)
217,700
Change in cash and cash equivalents in the year
1241,969)
217,700
Cash and cash equivalents at the beginning of the year
542,302
324,602
Cash and cash equivalents at the end of the year
300,333
542,302
The notes on pages 17 to 28 form part of these financial statements.
Page 16

Docusign Envelope ID.. 14770F95-1E644728-A9EA-B67631C542AD
DEMENTIA RESEARCH UK
(A Company Limited by Guarantee)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 OCTOBER 2024
General information
Dementia Research UK is a private Company, limited by guarantee, incorporated in England and Wales
(08236220). The principal address of the Group is 207 Regent Steet, London, W1 B 3HH.
Accounting policies
2.1 Basis of preparation of financial statements
The financial statements are prepared in Steding (£) which is the functional currency of the Group.
The financial statements are for the year ended 31 October 2024 (2023: year ended 31 October
2023).
The financial statements have been prepared in accordan￿ with the Charities SORP {FRS 102) -
Accounting and Reporting by Charities.. Statement of Recommended Practi￿ applicable to charities
preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK
and Republic of Ireland {FRS 102) (effective 1 January 2019), the Financial Reporting Standard
applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.
Dementia Research UK meets the definition of a public benefit entity under FRS 102. Assets and
liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the
relevant accounting policy.
On 1 November 2022 the charity established a trading company, Dementia Research Trading
Limited, to manage its future trading operations. The Consolidated statement of financial activities
(SOFA). Consolidated balan￿ sheet and the notes to the financial statements for the current year
consolidate the financial statements of the charity and its subsidiary undertaking. The results of the
subsidiary are consolidated on a line by line basis.
The charity has taken advantage of the exemption allowed under section 408 of the Companies Act
2006 and has not presented its own Statement of financial activities in these financial statements.
The parent charity made a loss of £55,914.
2.2 Going concern
The financial statements have been prepared on a going concern basis. which assumes that the
Company will continue in operational existence for the foreseeable future which the Trustees believe
to be appropriate.
The Charity continues to be able to reassure its donors. beneficiaries and stakeholders that the
activity at the core of its fundraising is stable and sustainable, and that it is well placed to meet its
objectives and to support its beneficiaries.
2.3 Company status
The Company is a company limited by guarantee. The members of the Company are the Trustees
named on page 1. In the event of the Company being wound up, the liability in respect of the
guarantee is limited to £1 per member of the Company.
Page 17

Docusign Envelope ID.. 14770F95-1E644728-A9EA-B67631C542AD
DEMENTIA RESEARCH UK
(A Company Limited by Guarantee)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 OCTOBER 2024
Accounting policies (continued)
2.4 Income
All income is recognised once the Company has entitlement to the income, it is probable that the
income will be received and the amount of income receivable can be measured reliably.
The recognition of income from legacies is dependent on establishing entitlement, the probability of
re￿Ipt and the ability to estimate with sufficient accuracy the amount re￿1Vable. Evidence of
entitlement to a legacy exists when the Company has sufficient evidence that a gift has been left to
them (through knowledge of the existen￿ of a valid will and the death of the benefactor) and the
executor is satisfied that the property in question will not be required to satisfy claims in the estate.
Re￿Ipt of a legacy must be recognised when it is probable that it will be re￿iVed and the fair value
of the amount receivable. which will generally be the expected cash amount to be distributed to the
Company, can be reliably measured.
2.5 Expenditure
Expenditure is recognised On￿ there is a legal or constructive obligation to transfer economic benefit
to a third party, it is probable that a transfer of economic benefit will be required in settlement and the
amount of the obligation can be measured reliably. Expenditure is classified by activity. The costs of
each activity are made up of the total of direct costs and shared costs, including support costs
involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly
to that activity. Shared costs which contribute to more than one activity and support costs which are
not attributable to a single activity are apportioned between those activities on a basis consistent with
the use of resources. Central staff costs are allocated on the basis of time spent.
Expenditure on raising funds includes all expenditure incurred by the Group to raise funds for its
charitable purposes and includes costs of all fundraising activities, events and non-charitable trading.
Expenditure on charitable activities is incurred on directly undertaking the activities which further the
Group's objectives, as well as any associated support costs.
Grants payable are charged in the year when the offer is made except in those cases where the offer
is conditional, such grants being recognised as expenditure when the conditions attaching are
fulfilled. Grants offered subject to conditions which have not been met at the year end are noted as a
commitment, but not accrued as expenditure.
All expenditure is inclusive of irrecoverable VAT.
2.6 Taxation
The Company is considered to pass the tests set out in Paragraph 1 Schedule 6 of the Finance Act
2010 and therefore it meets the definition of a charitable company for UK corporation tax purposes.
Accordingly. the Company is potentially exempt from taxation in respect of income or capital gains
received within categories covered by Chapter 3 Part 11 of the Corporation Tax Act 2010 or Section
256 of the Taxation of Chargeable Gains Act 1992, to the extent that such income or gains are
applied exclusively to charitable purposes.
2.7 Investments
Fixed asset investments are an amount equal to the capital contribution provided to the trading
subsidiary to contribute towards its working capital and trading activities.
Investments in subsidiaries are valued at cost less provision for impairment.
Page 18

Docusign Envelope ID.. 14770F95-1E644728-A9EA-B67631C542AD
DEMENTIA RESEARCH UK
(A Company Limited by Guarantee)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 OCTOBER 2024
Accounting policies (continued)
2.8 Stocks
Stocks are valued at the lower of cost and net realisable value after making due allowance for
obsolete and slow-moving stocks.
2.9 Debtors
Short-term debtors are initially measured at transaction price, less any impairment, and are
subsequently measured at their settlement value.
2.10 Cash at bank and in hand
Cash at bank and in hand includes cash and short-term highly liquid investments with a short maturity
of three months or less from the date of acquisition or opening of the deposit or similar account.
2.11 Liabilities
Liabilities are recognised when Ihere is an obligation at the Balance sheet date as a result of a past
event. it is probable that a transfer of economic benefit will be required in settlement, and the amount
of the settlement can be estimated reliably.
Liabilities are recognised at the amount that the Company anticipates it will pay to settle the debt or
the amount it has re￿iVed as adVan￿d pa￿nentS for the goods or services it must provide.
2.12 Financial instruments
The Group only enters into basic financial instrument transactions that result in the recognition of
financial assets and liabilities.
All financial assets and liabilities are initially measured at transaction price and subsequently
measured at their settlement value.
2.13 Pensions
The Group operates a defined contribution pension scheme and the pension charge in the SOFA
represents the amounts payable by the Group to the fund in respect of the year.
2.14 Fund accounting
General funds are unrestricted funds which are available for use at the discretion of the Trustees in
furtherance of the general objectives of the Group and which have not been designated for other
purposes.
Restricted funds are funds which are to be used in accordance with specific restrictions imposed by
donors or which have been raised by the Group for particular purposes. The costs of raising and
administering such funds are charged against the specific fund. The aim and use of each restricted
fund is set out in the notes to the financial statements.
Page 19

Docusign Envelope ID.. 14770F95-1E644728-A9EA-B67631C542AD
DEMENTIA RESEARCH UK
(A Company Limited by Guarantee)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 OCTOBER 2024
Judgements in applying accounting policies and key sources of estimation uncertainty
Preparation of the financial statements requires management to make significant judgements and
estimates in determining the carrwng amounts of ￿rtain assets and liabilities. The management's
estimates and assumptions are based on historical experien￿ and expectation of future events and are
reviewed periodically. Areas of significant judgement include the recoverability of intercompany debtors,
the carrying value of investments in the subsidiary company and the basis of expenditure
rechargeslallocations.
Income from donations and legacies
Unrestricted
funds
2024
Total
funds
2024
Total
funds
2023
Donations
581,649
365,757
581,649
365,757
357,070
691,186
Legacies
947,406
947,406
1.048,256
All income from donations and legacies in the prior year was unrestricted.
Expenditure on raising funds
Costs of raising voluntary income
Total
funds
Restated
2023
Unrestricted
funds
2024
Total
funds
2024
Campaigning
Communications
IT ServI￿S
162,164
38,643
40,708
162,164
38,643
40,708
147,537
37,032
18,228
241,515
241,515
202,797
Costs of raising voluntary income have been further analysed in 2024 (restated 2023 comparatives).
Campaigning costs for 2023 have been restated (increase of £33,799) following a reallocation from
education costs.
Page 20

Docusign Envelope ID.. 14770F95-1E644728-A9EA-B67631C542AD
DEMENTIA RESEARCH UK
(A Company Limited by Guarantee)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 OCTOBER 2024
Expenditure on raising funds (continued)
Fundraising trading expenses
Unrestricted
funds
2024
Total
funds
2024
Total
funds
2023
Other fundraising expenses
Wages and salaries
Social security costs
Pension costs
6.818
28,156
9.931
3,450
6,818
28,156
9,931
3,450
37,243
4,068
3,400
48,355
48,355
44,711
All fundraising trading expenses in 2023 were unrestricted.
Analysis of grants
Grants to
Institutions
2024
Total
funds
2024
Total
funds
2023
Charitable aclivities
357,500
357,500
385,000
All grants to institutions in 2023 were unrestricted.
Analysis of expenditure by activities
Activities
undertaken
directly
2024
Grant
funding of
activities
2024
Support
costs
2024
Total
funds
2024
Total
funds
2023
Governan￿ costs
25,285
89,869
25,285
736,520
21,647
620,145
Charitable activities
289.151
357.500
289.151
357,500
115,154
761,805
641,792
Page 21

Docusign Envelope ID.. 14770F95-1E644728-A9EA-B67631C542AD
DEMENTIA RESEARCH UK
(A Company Limited by Guarantee)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 OCTOBER 2024
Analysis of expenditure by activities (continued)
Analysis of direct costs
Total
funds
Restated
2023
Total
funds
2024
Staff costs
41,536
241,515
6,100
44,711
135,200
4,126
Education
Sundries
289,151
184,037
All direct costs inCu￿ed in 2023 were unrestricted.
Education costs for 2023 have been restated (reduction of £33,799) and reallocated to campaigning
costs.
Analysis of support costs
Total
funds
Restated
2023
Governance
costs
2024
Charitable
activities
2024
Total
funds
2024
Consulting
Secretarial
37,204
27,075
8.737
12,786
4.067
37,204
27,075
8,737
12,786
4,067
25,285
33,155
2,447
4,102
8,286
3,118
21,647
Office costs
Website
Finance
Governance costs
25.285
25.285
89,869
115,154
72,755
All support costs incurred in 2023 were unrestricted.
Support costs have been further analysed in 2024 (restated 2023 comparatives).
Page 22

Docusign Envelope ID.. 14770F95-1E644728-A9EA-B67631C542AD
DEMENTIA RESEARCH UK
(A Company Limited by Guarantee)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 OCTOBER 2024
Net incomel(expenditure)
Net incomel(expenditure) of the Group is stated after charging:
2024
2023
Auditor's remuneration
16,000
12,500
Auditorfs remuneration
The audilor's remuneration amounts to an auditor fee of £12.000 (2023 - £10,000). and accounting and
tax compliance fee of £4,000 (2023 - £2.500).
10. Staff costs
Group
2024
Group
2023
Company
2024
Company
2023
Wages and salaries
Social security costs
Pension costs
56,312
19,861
6,900
74,486
8,136
6,800
28,156
9,930
3,450
83,073
89,422
41,536
The average number of persons employed by the Company during the year was as follows..
Group
2024
No.
Group
2023
No.
Staff members
No employee received remuneration amounting to more than £60,000 in either year.
The total employee benefits of the key management personnel of the Group were £43,312 (2023:
£47.313).
11.
Trustees. remuneration and expenses
There were no trustees, remuneration or other benefits for the year ended 31 October 2024 nor for the
year ended 31 October 2023.
There were no Trustees, expenses paid for the year ended 31 October 2024 nor for the year ended 31
October 2023.
Page 23

Docusign Envelope ID.. 14770F95-1E644728-A9EA-B67631C542AD
DEMENTIA RESEARCH UK
(A Company Limited by Guarantee)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 OCTOBER 2024
12.
Fixed asset investments
Investments
in
subsidiary
companies
Company
Cost or valuation
At 1 November 2023
100,002
At 31 October 2024
100,002
Net book value
At 31 October 2024
100,002
At 31 October 2023
100,002
Principal subsidiaries
The following was a subsidiary undertaking of the Company.
Name
Company
number
Class of
shares
Holding
Included in
consolidation
Dementia Research Trading Limited
14455544
Ordinary
1000/0 Yes
The financial results of the subsidiary for the year were..
Name
Expenditure
ProfiU(Loss)
I Surplusl
(Deficit) for
the year
Net
(liabilities}I
assets
Dementia Research Trading Limited
{48,355)
48,355
{38,307)
13.
Stocks
Group
2024
Group
2023
Goods for resale
18,048
Page 24

Docusign Envelope ID.. 14770F95-1E644728-A9EA-B67631C542AD
DEMENTIA RESEARCH UK
(A Company Limited by Guarantee)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 OCTOBER 2024
14.
Debtors
Group
2024
Group
2023
Company
2024
Company
2023
Due within one year
Amounts owed by group undertakings
Prepayments and accrued income
75,000
100,829
101.064
42,970
42,835
101.064
42,970
175,829
42,835
15.
Creditors: Amounts falling due within one year
Group
Group
2023
Restated
Company
Company
2023
Restated
2024
2024
Trade creditors
17,460
39,412
17,460
21,190
39,412
Amounts owed to group undertakings
Other creditors
Accruals and deferred income
2,782
16,809
22,500
12,461
13,236
56,000
16,809
22,500
13,236
56,000
Grants payable
59,551
121,109
77,961
108,650
Page 25

Docusign Envelope ID.. 14770F95-1E644728-A9EA-B67631C542AD
DEMENTIA RESEARCH UK
(A Company Limited by Guarantee)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 OCTOBER 2024
16.
Statement of funds
Statement of funds - current year
Balance at 1
November
2023
Balance at
31 October
2024
Income Expenditure
Unrestricted funds
Charity funds
Subsidiary reserves
554,117
(89.954)
947,406
(1,003,320)
498,203
(48,355) (138,309)
464,163
947,406 (1.051,675)
359,894
Statement of funds - prior year
Charity only
Balance at
1 November
2022
Balance at
31 October
2023
Income Expenditure
Unrestricted funds
Charity funds
Subsidiary reserves
305.207
1.048.256
(799,346)
(89,954)
554,117
(89,954)
305,207
1,048,256
(889,300)
464,163
17. Analysis of net assets between funds
Analysis of net assets between funds - current period
Unrestricted
funds
2024
Total
funds
2024
Current assets
Creditors due within one year
419,445
(59,551)
419,445
(59,551)
Total
359,894
359,894
Page 26

Docusign Envelope ID.. 14770F95-1E644728-A9EA-B67631C542AD
DEMENTIA RESEARCH UK
(A Company Limited by Guarantee)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 OCTOBER 2024
17.
Analysis of net assets between funds (continued)
Analysis of net assets between funds - prior period
Unrestricted
funds
2023
Total
funds
2023
Current assets
585,272
585,272
(121,109) (121,109)
Creditors due within one year
Total
464,163
464,163
18.
Reconciliation of net movement in funds to net cash flow from operating activities
Group
2024
Group
2023
Net incomelexpenditure for the period (as per Statement of Financial
Activities)
(104,269)
158,956
Adjustments for:
Increase in stocks
(18,048)
(58,094)
(61,558)
Increase in debtors
(7,162)
65,906
(Decrease)lincrease in creditors
Net cash provided byl(used in) operating activities
(241,969)
217,700
19.
Analysis of cash and cash equivalents
Group
2024
Group
2023
Cash in hand
300,333
542,302
Total cash and cash equivalents
300,333
542,302
Page 27

Docusign Envelope ID.. 14770F95-1E644728-A9EA-B67631C542AD
DEMENTIA RESEARCH UK
(A Company Limited by Guarantee)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 OCTOBER 2024
20.
Analysis of changes in net debt
At1
November
2023 Cash flows
At31
October
2024
Cash at bank and in hand
542.302
(241,969)
300,333
542,302
(241,969)
300,333
21.
Pension commitments
The Group operates a defined contribution pension scheme. The assets of the scheme are held
separately from those of the Group in an independently administered fund. The pension cost charge
represents contributions payable by the Group to the fund. £575 (2023 - £550) was payable to the fund at
the balance sheel date and is included in creditors.
22. Related party transactions
Dementia Research Trading Limited. a wholly owned subsidiary of the charity. entered into a loan
agreement with the charity during the year whereby the charity agreed to loan the company up to
£100,000 per year over the next 5 years. During the year, £75,000 was loaned from the charity to the
company and remains outstanding at the year end.
Dementia Research Trading Limited recharged the charity £41.536 (2023: £nil) for salary costs incurred.
At the year end, the charity owed Dementia Research Trading Limited £21,19012023: £nil).
23. Controlling party
The Trustees make up the membership of the charitable company. There is no overall controlling party.
Page 28